How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis.
Fabrizio MartoraClaudio MarascaVincenzo PiconeLuigi FornaroMatteo MegnaGabriella FabbrociniPublished in: Journal of clinical medicine (2023)
We conducted a one-year prospective study involving the enrollment of 58 patients with Hidradenitis Suppurativa. Through a retrospective analysis of data on the same patients, with reference to the year prior to the initiation of the anti-TNFα drug adalimumab, we aimed to show how the advent of this biologic therapy changes the number of days of antibiotic therapy, the number of flare-ups per year, and their duration in days, as well as the quality of life and perceived pain of patients.
Keyphrases
- hidradenitis suppurativa
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- prognostic factors
- mental health
- stem cells
- emergency department
- physical activity
- depressive symptoms
- spinal cord
- big data
- mesenchymal stem cells
- cell therapy
- artificial intelligence
- data analysis
- replacement therapy